Crucell N.V. (CRXL) Launches Global Brand To Reflect And Reinforce Its Leading Position In Healthcare Innovation
11/16/2009 11:10:03 AM
More...
|
TapImmune Inc. (TPIM) Signs License Agreement With Crucell N.V. (CRXL)
11/5/2009 8:53:43 AM
More...
|
TapImmune Inc. (TPIM) Signs License Agreement With Crucell N.V. (CRXL)
11/4/2009 8:28:16 AM
More...
|
Crucell N.V. (CRXL) Q3 Profit Falls 22%, Keeps Outlook
11/3/2009 7:33:06 AM
More...
|
Crucell N.V. (CRXL) HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris
10/21/2009 11:19:54 AM
More...
|
Crucell N.V. (CRXL) Rabies Monoclonal Antibody Combination: Positive Results Philippines Phase II Study Presented at RITA Conference
10/20/2009 10:47:53 AM
More...
|
Crucell N.V. (CRXL) Strengthens its Vaccine Sales in the UK with a Dedicated Marketing and Sales Organization
9/30/2009 10:52:17 AM
More...
|
Johnson & Johnson (JNJ) and Crucell N.V. (CRXL) Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment
9/28/2009 10:48:45 AM
More...
|
Johnson & Johnson (JNJ) Buys 18% Stake in Crucell N.V. (CRXL) for $444 Million
9/28/2009 6:43:55 AM
More...
|
Crucell N.V. (CRXL) Wins $41 Million Flu Contract from U.S. Government
8/18/2009 6:46:03 AM
More...
|
|